Opus Genetics (IRD) CEO George Magrath Sells $34K of Stock
Key Points
- George Magrath, the CEO of Opus Genetics, sold 9,591 shares at a price of $3.58 each on October 23, 2026.
- After this sale, he holds about 2,038,894 shares, a decrease of 0.47% in his ownership.
- Opus Genetics shares recently traded around $3.46, significantly below their 52-week high of $7.07.
Since the trade, $IRD is down 0.3% to date (from the $3.47 close on Oct 23, 2026).
Get Opus Genetics text alerts
We text you when insiders, Congress, analysts or big funds move on $IRD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Opus Genetics, Inc. alert may contain errors. Disclosures
George Magrath, the Chief Executive Officer of Opus Genetics, Inc. (IRD), sold 9,591 shares on October 23, 2026, for about $34,384. This transaction was reported in a Form 4 filing with the SEC. Following the sale, he retains about 2,038,894 shares, marking a slight decrease of 0.47% in his total ownership.
IRD
Opus Genetics, Inc.
George Magrath vs. the S&P 500
Hypothetical returns from George Magrath's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Opus Genetics
Caligan Partners, LP holds 6,077,084 shares of Opus Genetics, valued at about $21,026,710. Adage Capital Partners GP L.L.C. has 6,029,775 shares worth approximately $20,863,021. Bios Capital Management, LP maintains 3,683,429 shares valued at about $12,744,664, while Balyasny Asset Management LP increased its stake by 369,913 shares, now owning 3,087,866 shares worth about $10,684,016. Nantahala Capital Management, LLC also saw significant activity, adding 1,380,033 shares for a total of 3,061,359 shares valued at about $10,592,302.
Opus Genetics, Inc. Stock Up 4.2%
On the day of Magrath's sale, Opus Genetics shares closed at $3.47. Recently, the stock has been trading around $3.46, which is below its 50-day moving average of $4.49 and its 200-day average of $4.15. The shares are currently more than 51% below their 52-week high of $7.07 but above their low of $1.70.
Recent Earnings
Opus Genetics reported trailing-twelve-month revenue of about $9.86 million, with a net margin of 0.0%. The company has a negative return on equity of -4796.5%. The next earnings report is scheduled for November 11, 2026.
Analysts Set New Price Targets
On October 22, 2026, Chardan Capital maintained a "Buy" rating on Opus Genetics with a price target of $16. Earlier, on October 16, Citizens reiterated a "Market Outperform" rating with a target of $17. Other firms have also expressed positive outlooks, with Wedbush maintaining an "Outperform" rating and a target of $13. The consensus target price among analysts is approximately $13.47.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company based in Durham, North Carolina. It focuses on developing gene therapies to treat inherited retinal diseases and other ophthalmic disorders. One of its key products is OPGx-LCA5, which is in clinical trials for early-onset retinal degeneration.
Bottom Line
Investors will be watching for the upcoming earnings report on November 11, 2026. With George Magrath's recent sale, it's important to consider how it fits into his overall trading pattern. The stock's performance relative to its moving averages and analyst ratings will also be key indicators to monitor.
Related Filing Alerts
Source: George Magrath's Form 4 filing on $IRD (Oct 23, 2026). Written by software, not financial advice. How we make alerts